martedì, 5 maggio 2026

Notizie AIOM – anno XV

Dalla malattia a una nuova visione della vita

In viaggio per guarire è il progetto che ha ricevuto il primo Italian Teacher Prize, premio nazionale insegnanti indetto dal MIUR (Ministero dell’Istruzione, Università e Ricerca), coordinato dalla prof.ssa Anna Berenzi della sezione ospedaliera dell’I.I.S. ...
Leggi tutto

MammaPrint Test Addressed in ASCO Breast Cancer Guideline Update

July 11, 2017 - New recommendations on the use of the MammaPrint genomic test issued on July 10 will help guide decisions on adjuvant systemic therapy for women with early breast cancer. The recommendations update the ASCO 2016 clinical practice guideline on the use of biomarkers ...
Leggi tutto

FDA Grants Abemaciclib Priority Review for HR+/HER2- Breast Cancer

July 10, 2017 - The FDA has granted a priority review to a new drug application (NDA) for abemaciclib as a treatment for patients with advanced hormone receptor (HR)positive, HER2-negative breast cancer, according to Eli Lilly and Company, the manufacturer of the CDK4/6 ...
Leggi tutto

FDA Grants Dasatinib Priority Review for Children With Ph+ Chronic Phase CML

July 10, 2017 - The FDA has accepted a supplemental new drug application (sNDA) for dasatinib for use in children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CP Ph+ CML). The agency also granted priority review for a powder for oral suspension ...
Leggi tutto

ODAC Recommends Approval of Gemtuzumab Ozogamicin for Newly-Diagnosed AML

July 11, 2017 - The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 6-1 in favor of approving gemtuzumab ozogamicin in combination with daunorubicin and cytarabine for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML). ...
Leggi tutto

FDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple NSCLC Therapies

July 12, 2017 - On June 22, the U.S. Food and Drug Administration (FDA) granted premarket approval to Thermo Fisher Scientific for the first next-generation sequencing–based test that simultaneously screens tumor samples for biomarkers associated with three FDA-approved ...
Leggi tutto

FDA Grants Full Approval to Blinatumomab for B-cell Precursor ALL

July 12, 2017 - The FDA has granted a full approval to blinatumomab as a treatment for adults and children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL), regardless of Philadelphia chromosome (Ph) status, according to the developer of the anti-CD19 ...
Leggi tutto

ODAC Unanimously Recommends Approval of BLA for Tisagenlecleucel in Relapsed/Refractory Pediatric ALL

July 12, 2017 - Citing “unprecedented clinical success” and calling the drug “potentially paradigm-changing,” the Oncologic Drugs Advisory Committee (ODAC) voted 10-0 today to recommend approval of a biologics license application (BLA) for tisagenlecleucel ...
Leggi tutto

CA-125: an inaccurate surveillance tool immediately after cytoreductive surgery and hyperthermic intraoperative chemotherapy (CRS-HIPEC)?

This study seeks to evaluate pre and post-operative CA-125 in patients undergoing complete cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), and understand the time frame before values normalise allowing use as a surveillance tool to resume. ...
Leggi tutto

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

Combination treatment with immune checkpoint inhibitors has shown enhanced antitumor activity compared with monotherapy in tumor types such as melanoma. The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab ...
Leggi tutto